Zoniporide: A potent and highly selective inhibitor of human Na+/H+ exchanger-1

European Journal of Pharmacology

Volumn 451, Issue 1, 2002, Pages 37-41

  Marala, Ravi B ^a   Brown, Janice A ^a   Kong, Jimmy X ^a   Tracey, W ^a   Knight, Delvin R ^a   Wester, Ronald T ^a   Sun, Dexue ^a   Kennedy, Scott P ^a   Hamanaka, Ernest S ^a   Ruggeri, Roger B ^a   Hill, Roger J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Na+ H+ exchanger; Platelet swelling assay

Indexed keywords

CARIPORIDE; ENIPORIDE; PROPIONATE SODIUM; PROPIONIC ACID DERIVATIVE; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; SODIUM PROTON EXCHANGE PROTEIN 2; SODIUM PROTON EXCHANGE PROTEIN 3; UNCLASSIFIED DRUG; ZONIPORIDE;

ANIMAL CELL; ARTICLE; ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; FIBROBLAST; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON SODIUM EXCHANGE; RAT; THROMBOCYTE;

CELLS, CULTURED; FIBROBLASTS; GUANIDINES; HUMANS; PYRAZOLES; SODIUM; SODIUM-HYDROGEN ANTIPORTER; SULFONES;

EID: 0037031544     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02193-3     Document Type: Article

References (25)

1. + antiporter inhibitors. J. Med. Chem. 40:1997;2017-2034.
2. + exchanger (NHE-2). Proc. Natl. Acad. Sci. 90:1993;3938-3942.
3. + antiporter isoforms using amiloride analogs and new inhibitor exhibiting anti-ischemic properties. Mol. Pharmacol. 44:1993;1041-1045.
4. + exchanger. Biochem. Cell. Biol. 76:1998;735-741.
5. Garcia M.L., King V.F., Shevell J.L., Slaughter R.S., Suarez-Kurtz G., Winquist R.J., Kaczorowski G.J. Amiloride analogs inhibit L-type calcium channels and display calcium entry blocker activity. J. Biol. Chem. 265:1990;3763-3771.
6. + exchange. Cardiovasc. Res. 35:1997;80-89.
7. Gumina R.J., Misumura T., Beier N., Schelling P., Schultz J.J., Gross G.J. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J. Pharmacol. Exp. Ther. 286:1998;175-183.
8. Guzman-Perez A., Wester R.T., Allen M.C., Brown J.A., Buchholz A.R., Cook E.R., Day W.W., Hamanaka E.S., Kennedy S.P., Knight D.R., Kowalcyk P.J., Marala R.B., Mularski C.J., Novomisle W.A., Ruggeri R.B., Tracey W.R., Hill R.J. Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg. Med. Chem. Lett. 11:2001;803-807.
9. + exchange inhibitor HOE694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart. Circulation. 89:1994;2787-2798.
10. Humphreys R.A., Haist J.V., Chakrabarti S., Feng Q., Arnold J.M.O., Karmazyn M. Orally administered NHE1 inhibitor cariporide reduces acute responses to coronary occlusion and reperfusion. Am. J. Physiol. 276:1999;H749-H757.
11. + exchange. Am. J. Physiol. 255:1988;H608-H615.
12. Karmazyn M. The sodium-hydrogen exchange system in the heart: its role in ischemic and reperfusion injury and therapeutic implications. Can. J. Cardiol. 12:1996;1074-1082.
13. Karmazyn M., Ray M., Haist J.V. Comparative effects of Na/H exchanger inhibitors against cardiac injury produced by ischemia/reperfusion, hypoxia/reoxygenation, and the calcium paradox. J. Cardiovasc. Pharmacol. 21:1993;172-178.
14. Knight D.R., Smith A.H., Flynn D.M., MacAndrew J.T., Ellery S.S., Kong J.X., Marala R.B., Wester R.T., Guzman-Perez A., Hill R.J., Magee W.P., Tracey W.R. Novel NHE-1 inhibitor, Zoniporide, reduces ischemic myocardial injury in vitro and in vivo. J. Pharmacol. Exp. Ther. 297:2001;254-259.
15. + exchangers. Molecular diversity and relevance to heart. Ann. N.Y. Acad. Sci. 874:1999;346-353.
16. Pierce G.N., Cole W.C., Liu K., Massaeli H., Maddaford T.G., Chen Y.J., McPherson C.D., Jain S., Sontag D. Modulation of cardiac performance by amiloride and several selected derivatives of amiloride. J. Pharmacol. Exp. Ther. 265:1993;1280-1291.
17. + exchange in platelets of patients with essential hypertension using an optical swelling assay. J. Hypertens. 9:1991;231-238.
18. + exchange inhibitor and its effects in cardiac ischemia. Br. J. Pharmacol. 109:1993;562-568.
19. Scholz W., Albus U., Counillon L., Gogelein H., Lang H.-J., Linz W., Weichert A., Scholkens B.A. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc. Res. 29:1995;260-268.
20. Tani M., Neely J.R. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Circ. Res. 65:1989;1045-1056.
21. Theroux P., Chaitman B.R., Danchin N., Erhardt L., Meinertz T., Schroeder J.S., Tognoni G., White H.D., Willerson J.T., Jessel A. Inhibition of the sodium-hydrogen exchanger with Cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation. 102:2000;3032-3038.
22. + exchangers. Physiol. Rev. 77:1997;51-74.
23. + exchange in isolated myocytes from adult rat heart. Am. J. Physiol. 257:1989;C207-C213.
24. + exchange inhibitors cariporide mesilate and (3-methanesulfonyl-4-piperidino-benzoyl)guanidine methanesulfonate. Arzneim.-Forsch. 47(II):1997;1204-1207.
25. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J. Am. Coll. Cardiol. 38(6):2001;1644-1650.